The pituitary tumor transforming gene in thyroid cancer

被引：14

作者：

Lewy, G. D. ^{[1
]}

Sharma, N. ^{[1
]}

Seed, R. I. ^{[1
]}

Smith, V. E. ^{[1
]}

Boelaert, K. ^{[1
]}

McCabe, C. J. ^{[1
]}

机构：

[1] Univ Birmingham, Inst Biomed Res, Sch Clin & Expt Med, Birmingham B15 2TH, W Midlands, England

来源：

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION | 2012年 / 35卷 / 04期

基金：

英国医学研究理事会;

关键词：

PTTG; thyroid cancer; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION FUNCTION; SODIUM-IODIDE SYMPORTER; PAPILLARY CARCINOMA; COLORECTAL-CANCER; BRAF MUTATIONS; DIFFERENTIATED CARCINOMAS; PROGNOSTIC-SIGNIFICANCE; CHROMATID SEPARATION; RET PROTOONCOGENE;

D O I：

10.3275/8332

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

The pituitary tumor transforming gene (PUG) is a multifunctional proto-oncogene that is over-expressed in various tumors including thyroid carcinomas, where it is a prognostic indicator of tumor recurrence. PUG has potent transforming capabilities in vitro and in vivo, and many studies have investigated the potential mechanisms by which PUG contributes to tumorigenesis. As the human securin, PUG is involved in critical mechanisms of cell cycle regulation, whereby aberrant expression induces aneuploidy. PUG may further contribute to tumorigenesis through its role in DNA damage response pathways and via complex interactions with hormones and growth factors. Furthermore, PUG over-expression negatively impacts upon the efficacy of radioiodine therapy in thyroid cancer, through repression of expression and function of the sodium iodide symporter. Given its various roles at all disease stages, PUG appears to be an important oncogene in thyroid cancer. This review discusses the current knowledge of PUG with particular focus on its role in thyroid cancer. (J. Endocrinol. Invest. 35: 425-433, 2012) (C)2012, Editrice Kurtis

引用

页码：425 / 433

页数：9

共 143 条

[1]

Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance [J].

Akslen, LA ;

LiVolsi, VA .

HUMAN PATHOLOGY, 2000, 31 (04) :439-442

[2]

[Anonymous], GUID MAN THYR CANC

[3]

Iodide symporter gene expression in human thyroid tumors [J].

Arturi, F ;

Russo, D ;

Schlumberger, M ;

du Villard, JA ;

Caillou, B ;

Vigneri, P ;

Wicker, R ;

Chiefari, E ;

Suarez, HG ;

Filetti, S .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (07) :2493-2496

[4]

Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors [J].

Arturi, F ;

Russo, D ;

Bidart, JM ;

Scarpelli, D ;

Schlumberger, M ;

Filetti, S .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (02) :129-135

[5]

Basik M, 1997, GENE CHROMOSOME CANC, V18, P19, DOI 10.1002/(SICI)1098-2264(199701)18:1<19::AID-GCC3>3.3.CO

[6]

2-2

[7]

Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis [J].

Bernal, JA ;

Luna, R ;

Espina, A ;

Lázaro, I ;

Ramos-Morales, F ;

Romero, F ;

Arias, C ;

Silva, A ;

Tortolero, M ;

Pintor-Toro, JA .

NATURE GENETICS, 2002, 32 (02) :306-311

[8]

PTTG and PBF repress the human sodium iodide symporter [J].

Boelaert, K. ;

Smith, V. E. ;

Stratford, A. L. ;

Kogai, T. ;

Tannahill, L. A. ;

Watkinson, J. C. ;

Eggo, M. C. ;

Franklyn, J. A. ;

McCabe, C. J. .

ONCOGENE, 2007, 26 (30) :4344-4356

[9]

Pituitary tumor transforming gene and fibroblast growth factor-2 expression: Potential prognostic indicators in differentiated thyroid cancer [J].

Boelaert, K ;

McCabe, CJ ;

Tannahill, LA ;

Gittoes, NJL ;

Holder, RL ;

Watkinson, JC ;

Bradwell, AR ;

Sheppard, MC ;

Franklyn, JA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :2341-2347

[10]

Bongarzone I, 1998, CLIN CANCER RES, V4, P223

← 1 2 3 4 5 6 7 8 9 10 →